PARP1 and cholangiocarcinoma: Building on this foundation, USP inhibitors should be combined with immune checkpoint blockers, FGFR inhibitors, or PARP inhibitors and evaluated in integrated cholangiocarcinoma models that combine patient-derived organoids, patient-derived xenograft (PDX) tumors, and humanized mice.